Company: QXO-PB
Filing Date: 2025-06-25
Form Type: 424B5
Source: 0001104659-25-062233
Chunk: 18

Company: QXO, Inc.
Filing Date: 2025-06-25
Form: 424B5
Chunk 18
---
 approximately $ if the underwriters exercise in full their option to purchase additional shares) after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds of this offering for general corporate purposes, which may include, among other things, funding future acquisitions of businesses, as described in the section titled “Use of Proceeds” in this prospectus supplement.

Risk factors

Investing in our Common Stock involves significant risks. See “Risk Factors” in this prospectus supplement, as well as other information included in or incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of the factors you should carefully consider before deciding to invest in our Common Stock.

NYSE symbol

“QXO.”

The number of shares of Common Stock to be outstanding immediately after this offering is based on 580,445,718 shares outstanding as of June 15, 2025 and gives effect to the issuance of shares of Common Stock (or shares of Common Stock if the underwriters exercise in full their option to purchase additional shares) in this offering, and excludes:

•

29,315,330 shares of Common Stock issuable upon vesting of restricted stock units (“RSUs”) or performance-based restricted stock units (“PSUs”) outstanding as of June 15, 2025;

•

2,292,526 shares of Common Stock issuable upon the exercise of options granted under the QXO, Inc. 2024 Omnibus Incentive Compensation Plan (the “Plan”) as of June 15, 2025, at a weighted-average exercise price of $5.14 per share;

•

approximately 32,677,626 additional shares of Common Stock that were available for issuance under the Plan as of June 15, 2025;

•

219,010,074 shares of Common Stock issuable upon conversion of shares of our Convertible Perpetual Preferred Stock outstanding as of June 15, 2025;

•

219,010,074 shares of Common Stock issuable upon the exercise of our warrants outstanding as of June 15, 2025, at a weighted-average exercise price of $7.42 per share;

•

42,000,000 shares of Common Stock issuable upon the exercise of our pre-funded warrants outstanding as of June 15, 2025, at a weighted-average exercise price of $0.00001 per share;

•

up to 34,848,450 shares of Common Stock underlying our outstanding Depositary Shares; and

<div